CD22 / Janelia Fluor 646 / pinatuzumab

Product Details
Supplier Novus Biologicals, a Bio-Techne brand
Catalog #: NBP3-28024JF646 (View supplier product page)
Size 100 μl
Price $379.00
Antigen CD22
Clone pinatuzumab
Host Human
Isotype IgG1
Conjugate Janelia Fluor 646
Target Species Human
Applications FC, ELISA, Functional
Description Siglec-2/CD22 Antibody (pinatuzumab) [Janelia Fluor® 646]
About CD22 and Janelia Fluor 646
CD22 Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. [provided by Alliance of Genome Resources, Apr 2022]
Janelia Fluor 646 Janelia Fluor® 646 was developed at the Janelia Campus of the Howard Hughes Medical Institute but is commercialized by other vendors. The Janelia Fluor®s family is unique in that the fluorophores are cell-permeable and are available in photoactivatable forms. These fluorophores were developed for super-resolution microscopy (STED, PALM and STORM) and live-cell microscopy in the HaloTag and SNAP-tag versions. Janelia Fluor® 646 has an excitation peak at 646 nm and an emission peak at 664 nm.
Citations
Additional
Sources
Reviews & Ratings
Submit a Review

Janelia Fluor 646 Excitation and Emission Spectra